Archemix has agreed to employ its know-how in discovering aptamer-based drugs for Pfizer in a new drug discovery pact. The details were kept confidential, but Archemix gains an unspecified upfront payment along with research funds and milestones in exchange for identifying drug candidates for thee targets specified by Pfizer. Aptamers target proteins that trigger diseases, thwarting the process. The Cambridge, MA-based Archemix is already engaged with Elan in a separate discovery pact.
- see the press release for details
- read the report on the deal from The Boston Globe
Related Articles:
Nuvelo expands collaboration pact with Archemix. Report
What's next for Pfizer? Report
Pfizer to axe 2,200 sales jobs in realignment. Report